API Holdings Limited Unlisted Shares
₹5
API Holdings Unlisted Shares Trend
This sentiment meter reflects current demand-supply conditions in the unlisted market. It is not a rating and should not be considered advice to buy, sell, or hold. Sentiments are subject to rapid change and may not be real-time.
API Holdings Limited Unlisted Shares - Create Price Alert
Want to stay updated? Add your target price and email, and we'll notify you.
API Holdings Unlisted Shares Details
About API Holdings
API Holdings, the parent company of PharmEasy, is one of India’s leading digital healthcare platforms, based on GMV of products and services sold for the year ended March 31, 2021, according to the RedSeer Report. API Holdings operates an integrated end-to-end healthcare ecosystem designed to address the evolving healthcare needs of consumers across multiple stages, including:
- Digital healthcare tools and wellness information
- Online doctor teleconsultation services
- Diagnostics and radiology test bookings
- Treatment delivery through medicines, healthcare products, and medical devices
API Holdings and PharmEasy have built strong proprietary technology platforms, unified healthcare data systems, advanced supply chain capabilities, and deep expertise in India’s healthcare ecosystem. These capabilities help differentiate API Holdings in the rapidly growing Indian digital healthcare market.
The API Holdings platform empowers every stakeholder across the healthcare value chain, including:
- Wholesalers, retailers, chemists, and healthcare institutions
- Doctors, consultants, hospitals, diagnostic centres, and radiology labs
- Consumers and patients
- Pharmaceutical, nutraceutical, and medical device companies
Through innovative technology solutions and a connected healthcare network, API Holdings enables these stakeholders to streamline operations, improve accessibility, and scale efficiently across India.
PharmEasy’s extensive logistics and last-mile delivery network allows API Holdings to serve customers across more than 18,587 pin codes as of June 2021. The platform has established a strong presence across urban, semi-urban, and rural India, making affordable and accessible healthcare services available to people across different income groups and geographies.
API Holdings continues to strengthen its position in the Indian digital healthcare sector through PharmEasy by expanding healthcare access, improving convenience, and leveraging technology-driven healthcare solutions at scale.
PharmEasy is one of India’s leading consumer healthcare “super apps,” offering a comprehensive digital healthcare platform for medicine delivery, diagnostics, and online healthcare services. PharmEasy enables consumers to conveniently access prescription medicines, OTC pharmaceutical products, healthcare and wellness products, diagnostic test services, and teleconsultations with doorstep delivery across India.
As a fast-growing digital healthcare platform under API Holdings, PharmEasy is transforming healthcare accessibility by combining technology, affordability, and convenience for millions of Indian consumers.
Key Highlights of PharmEasy
- 25 Million+ Total Users
- 8.8 Million+ Total Orders
- 2.4 Million+ Transacting Customers
Services Offered by PharmEasy
- Online Medicine Ordering and Home Delivery
- OTC Medicines and Healthcare Products
- Diagnostic and Lab Test Bookings
- Preventive Healthcare and Wellness Products
- Online Doctor Teleconsultation Services
PharmEasy’s technology-driven healthcare ecosystem allows users to manage their healthcare needs through a single platform, making it one of India’s most recognized digital healthcare and online pharmacy brands.
API Holdings has built a diversified digital healthcare ecosystem through multiple healthcare and technology-driven brands operating across pharmaceuticals, diagnostics, hospital procurement, and healthcare software solutions. Through its portfolio companies and platforms, API Holdings is strengthening its position in India’s rapidly growing healthcare and health-tech sector.
API Holdings: Businesses & Brands
- Aknamed – A technology-enabled hospital supplies procurement platform that helps hospitals and healthcare institutions streamline medical procurement and supply chain operations.
- Docon – An EMR (Electronic Medical Records) and practice management software platform designed for clinics, doctors, and healthcare professionals to manage patient records, appointments, and clinical workflows efficiently.
- PharmEasy – One of India’s largest online pharmacy marketplaces offering medicine delivery, healthcare products, diagnostic services, and teleconsultation solutions.
- Retailio – One of India’s leading B2B pharma platforms connecting pharmacies, retailers, and wholesalers through a technology-driven pharmaceutical distribution network.
- Thyrocare – One of India’s largest diagnostic testing and preventive healthcare service providers by testing volumes.
Through these healthcare brands and digital platforms, API Holdings continues to expand its integrated healthcare ecosystem across consumers, pharmacies, hospitals, diagnostics, and healthcare professionals in India.
API Holdings Financials
Income Statement
Figures shown in millions. YoY shown under each year; trend sparkline on the right.
| Particulars | FY 2021-22 | FY 2022-23 | FY 2023-24 | FY 2024-25 | Trend |
|---|---|---|---|---|---|
| Income | |||||
| Revenue from operations | 57,288.21 | 66,439.38 | 56,642.86 | 58,721.64 | |
| Other income | 521.81 | 558.33 | 946.55 | 1,078.65 | |
| Total income | 57,810.02 | 66,997.71 | 57,589.41 | 59,800.29 | |
| Expenses | |||||
| Cost of Material Consumed | 854.60 | 1,569.20 | 1645.09 | 1,886.02 | |
| Purchase of stock-in-trade | 52,566.12 | 55,120.60 | 45,728.06 | 47,295.83 | |
| Changes in inventories of stock-in-trade | (2,290.53) | 618.96 | 1,430.14 | (39.76) | |
| Employee benefits expense | 14,589.71 | 12,833.20 | 6,993.63 | 9,083.99 | |
| Finance costs | 2,582.64 | 6,655.43 | 7,279.16 | 5,061.07 | |
| Depreciation and amortisation expense | 1,587.85 | 2,434.40 | 2,159.52 | 1,689.78 | |
| Other expenses | 15,025.51 | 10,508.31 | 5,619.76 | 6,107.40 | |
| Total expenses | 84,915.90 | 89,740.10 | 72,548 | 72,085.58 | |
| Loss before exceptional items and tax | (27,105.88) | (22,745.38) | (14,949.84) | (12,203.74) | |
| Loss before tax | (39,707.70) | (51,965.22) | (25,219.72) | (15,168.85) | |
| Total tax expense | 217.26 | 152.12 | 115.41 | 555.04 | |
| Loss for the year | (39,924.96) | (52,117.34) | (25,311.71) | (15,723.89) | |
| EPS (in ₹) | (7.28) | (8.51) | (3.02) | (1.05) |
API Holdings Unlisted Shares - Key Insights
-
NO EFFECT
Total Revenue Grew Steadily
Total Revenue increased by approximately 3.84%, climbing from ₹57,589.41 million in FY 23-24 to ₹59,800.29 million in FY 24-25.
-
POSITIVE IMPACT
Loss After Tax Reduced Significantly
The company successfully slashed its net losses by an impressive 39.85%, dropping from ₹25,219.72 million in FY 23-24 to ₹15,168.85 million in FY 24-25.
-
POSITIVE IMPACT
EPS Improved
Loss per share saw a remarkable 65.23% improvement, decreasing sharply from a loss of ₹3.02 in FY 23-24 to just ₹1.05 in FY 24-25.
Similar Stocks
API Holdings Unlisted Shares - Corporate Actions
Share Buyback Programs
No active buybacks
There are currently no active or upcoming share buyback programs announced for this security.
API Holdings Unlisted Shares - News
FINANCIAL EXPRESS
‘Expect PBT break-even for the group co by Q4 FY27’: Rahul Guha, MD & CEO API Holdings
API Holdings CEO Rahul Guha discusses the group’s roadmap to profitability, highlighting PharmEasy’s recent monthly break-even and Thyrocare’s 50% PAT growth.
BUSINESS STANDARD
PharmEasy sets stage for IPO return with new strategy, boosted cash flow
PharmEasy plans to re-enter the IPO market following a major business overhaul. The company aims to discuss its IPO strategy, including a potential merger with Thyrocare, at its February board meeting
MONEYCONTROL
Manipal Group to lead Rs 2,500 crore investment in PharmEasy at massive drop in valuation: Sources
The Manipal Group family office may also secure a board seat at API Holdings and become its single largest shareholder
BUSINESS STANDARD
API Holdings' Rs 3,500 cr rights issue oversubscribed: Dhaval Shah
PharmEasy's parent API Holdings recently conducted a Rs 3,500 crore rights issue and it has been over-subscribed, claimed co-founder Dhaval Shah.
LIVEMINT
Naspers, Temasek get CCI approval to purchase stakes in PharmEasy
CCI has approved the purchase of stakes in PharmEasy by various entities including Naspers, Temasek, Goldman Sach, etc.
‘Expect PBT break-even for the group co by Q4 FY27’: Rahul Guha, MD & CEO API Holdings
API Holdings CEO Rahul Guha discusses the group’s roadmap to profitability, highlighting PharmEasy’s recent monthly break-even and Thyrocare’s 50% PAT growth.
PharmEasy sets stage for IPO return with new strategy, boosted cash flow
PharmEasy plans to re-enter the IPO market following a major business overhaul. The company aims to discuss its IPO strategy, including a potential merger with Thyrocare, at its February board meeting
Manipal Group to lead Rs 2,500 crore investment in PharmEasy at massive drop in valuation: Sources
The Manipal Group family office may also secure a board seat at API Holdings and become its single largest shareholder
API Holdings' Rs 3,500 cr rights issue oversubscribed: Dhaval Shah
PharmEasy's parent API Holdings recently conducted a Rs 3,500 crore rights issue and it has been over-subscribed, claimed co-founder Dhaval Shah.
Naspers, Temasek get CCI approval to purchase stakes in PharmEasy
CCI has approved the purchase of stakes in PharmEasy by various entities including Naspers, Temasek, Goldman Sach, etc.
No documents found
Try adjusting your search or filters.
API Holdings Limited Unlisted Shares Shares
Quick enquiry - tell us what you want and we'll reach out via WhatsApp or email.
API Holdings Unlisted Shares Trend
This sentiment meter reflects current demand-supply conditions in the unlisted market. It is not a rating and should not be considered advice to buy, sell, or hold. Sentiments are subject to rapid change and may not be real-time.
API Holdings Limited Unlisted Shares - Create Price Alert
Set a target price and we'll notify you when it's reached.
FAQ's 
